Deutsche Bank Starts Aegerion Pharmaceuticals (AEGR) at Buy; See Approval in 2012 Likely for Lomitapide

Article Stock Quotes (1) Comments (0)

Deutsche Bank initiates coverage on Aegerion Pharmaceuticals (NASDAQ: AEGR) with a Buy. PT $19.00.

Deutsche analyst says, "Aegerion belongs to a group of biotech companies that are categorized as "orphan drug" companies because they develop & sell drugs for very rare diseases (<200KUS patients). Aegerion is developing a pill, Lomitapide, for a rare disease called HoFH that is associated with high cholesterol levels and early death. We rate the stock a Buy because we believe the current stock price does not reflect full FDA approval or the full potential for Lomitapide in HoFH and FC. Next catalysts: long term 78 week data YE2011, FDA approval mid 2012."

For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $14.97 yesterday, with a 52 week range of $9.00-$25.92.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
• Wells Fargo Starts Taylor Morrison Home (TMHC) at Outperform
• Standpoint Research Starts Vera Bradley (VRA) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Deutsche Bank

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?